![]() ![]() Today, we’ll talk about some of the key points in the TREATMENT APPROACH FOR PRIMARY PREVENTION PATIENTS.īefore I get into the treatment approach for primary prevention patients (those without cardiovascular disease or a statin indicated condition), let’s first review some of the highlights of screening for dyslipidemia (cholesterol check): ![]() TREATMENT APPROACH FOR PEOPLE WITH ESTABLISHED ATHEROSCLEROTIC VASCULAR DISEASE.(familial hypercholesterolemia, genetic dyslipidemia, chronic kidney disease, diabetes) TREATMENT APPROACH FOR PRIMARY PREVENTION PATIENTS WITH A STATIN INDICATED CONDITION.TREATMENT APPROACH FOR PRIMARY PREVENTION PATIENTS.I am splitting up my lipid guideline blogging into three parts, focusing on treatment, and following the figures (pg 37-39) for treatment in the guidelines: the lack of CV benefit of omega-3 fatty acids from supplements or dietary sources.CV benefit of icosapent ethyl in patients with triglycerides 1.5-5.6mmol/L and a prior CV event, or with diabetes and additional risk factors.guidance on who will benefit most from adding PCSK9 inhibitor to statin therapy (how to choose vs ezetimibe?).preventive care of women with hypertensive (high blood pressure) disorders of pregnancy.the role of coronary artery calcium (CAC) scoring in deciding whether or not to recommend statin therapy.different cholesterol thresholds for different groups of people, for intensifying treatment with non-statin agents.changes in how to screen for dyslipidemia.The recently released 2021 Canadian lipid guidelines provides updated recommendations based on important new evidence since the last iteration of the guidelines in 2016. We know that optimizing lipid (cholesterol) levels is an important part of reducing the risk of cardiovascular disease. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |